JPH09512704A - シグナル変換経路を調節するための産物および方法 - Google Patents

シグナル変換経路を調節するための産物および方法

Info

Publication number
JPH09512704A
JPH09512704A JP7524210A JP52421095A JPH09512704A JP H09512704 A JPH09512704 A JP H09512704A JP 7524210 A JP7524210 A JP 7524210A JP 52421095 A JP52421095 A JP 52421095A JP H09512704 A JPH09512704 A JP H09512704A
Authority
JP
Japan
Prior art keywords
peptide
binding
arh1
amino acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7524210A
Other languages
English (en)
Japanese (ja)
Inventor
ジヨン・シー キヤンビア，
クリストフアー・エム プレイマン，
マーカス・アール クラーク，
Original Assignee
ナシヨナル・ジユーイツシユ・センター・フオー・イミユノロジー・アンド・レスピラトリー・メデイシン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナシヨナル・ジユーイツシユ・センター・フオー・イミユノロジー・アンド・レスピラトリー・メデイシン filed Critical ナシヨナル・ジユーイツシユ・センター・フオー・イミユノロジー・アンド・レスピラトリー・メデイシン
Publication of JPH09512704A publication Critical patent/JPH09512704A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP7524210A 1994-03-17 1995-03-17 シグナル変換経路を調節するための産物および方法 Pending JPH09512704A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21511694A 1994-03-17 1994-03-17
US215,116 1994-03-17
PCT/US1995/003438 WO1995024915A1 (fr) 1994-03-17 1995-03-17 Produit et procede de regulation des voies de transduction de signaux

Publications (1)

Publication Number Publication Date
JPH09512704A true JPH09512704A (ja) 1997-12-22

Family

ID=22801724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7524210A Pending JPH09512704A (ja) 1994-03-17 1995-03-17 シグナル変換経路を調節するための産物および方法

Country Status (4)

Country Link
EP (1) EP0804218A1 (fr)
JP (1) JPH09512704A (fr)
CA (1) CA2184631A1 (fr)
WO (1) WO1995024915A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537357A (ja) * 1999-02-25 2002-11-05 ナショナル ジューイッシュ メディカル アンド リサーチ センター 受容体脱感作に関連する症状を治療するための生産物及び方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976819A (en) * 1995-11-21 1999-11-02 National Jewish Medical And Research Center Product and process to regulate actin polymerization in T lymphocytes
WO1998017323A1 (fr) * 1996-10-23 1998-04-30 The Trustees Of The University Of Pennsylvania Vaccins perfectionnes
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
WO2003006060A1 (fr) * 2001-07-09 2003-01-23 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de la liaison au domaine sh3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667803B2 (en) * 1991-01-18 1996-04-18 New York University A receptor tyrosine kinase target protein cDNA cloning method and hGRB proteins
US5352660A (en) * 1991-10-31 1994-10-04 Mount Sinai Hospital Corporation Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
US5770396A (en) * 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
AU6098194A (en) * 1993-01-29 1994-08-15 Ariad Pharmaceuticals, Inc. Analogs of receptor tyrosine activation motifs and therapeutic uses thereof
WO1994018832A1 (fr) * 1993-02-26 1994-09-01 Dana-Farber Cancer Institute, Inc. Modulation a mediation cd4 de kinases lipidiques
CA2142713A1 (fr) * 1993-06-30 1995-01-12 Paolo Comoglio Inhibiteurs peptidiques de la mitose et de la motogenese
DE69534920T2 (de) * 1994-07-22 2007-04-05 University Of North Carolina Src SH3 BINDENDE PEPTIDE UND VERFAHREN ZU IHRER ISOLIERUNG UND VERWENDUNG
CA2247207A1 (fr) * 1995-02-28 1996-09-06 National Jewish Center For Immunology And Respiratory Medicine Composes de peptidyl comprenant un motif structural itim regulant la fonction hematopoietique et leur utilisation
US7815749B2 (en) * 2006-06-29 2010-10-19 Hitachi Metals, Ltd. Method for manufacturing semi-hard magnetic material and semi-hard magnetic material

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537357A (ja) * 1999-02-25 2002-11-05 ナショナル ジューイッシュ メディカル アンド リサーチ センター 受容体脱感作に関連する症状を治療するための生産物及び方法

Also Published As

Publication number Publication date
AU2187495A (en) 1995-10-03
AU699662B2 (en) 1998-12-10
CA2184631A1 (fr) 1995-09-21
WO1995024915A1 (fr) 1995-09-21
EP0804218A1 (fr) 1997-11-05
EP0804218A4 (fr) 1997-11-12

Similar Documents

Publication Publication Date Title
Mori et al. Identification of two juxtamembrane autophosphorylation sites in the PDGF beta‐receptor; involvement in the interaction with Src family tyrosine kinases.
Yokoyama et al. BANK regulates BCR‐induced calcium mobilization by promoting tyrosine phosphorylation of IP3 receptor
JP3462498B2 (ja) レセプターチロシンキナーゼ標的タンパク質のｃＤＮＡクローニング方法及びｈＧＲＢタンパク質
West et al. The role of ADP-ribosylation factor and phospholipase D in adaptor recruitment
Campbell et al. Identification of regions in polyomavirus middle T and small t antigens important for association with protein phosphatase 2A
Ingham et al. The Gab1 docking protein links the b cell antigen receptor to the phosphatidylinositol 3-kinase/Akt signaling pathway and to the SHP2 tyrosine phosphatase
US6537804B1 (en) BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth
JP2001136987A (ja) ホスホジエステラーゼ酵素
Piwnica-Worms et al. Regulation of pp60c-src and its interaction with polyomavirus middle T antigen in insect cells
US20140179608A1 (en) Materials and Methods Related to Sodium/Potassium Adenosine Triphosphatase and SRC
Deppert et al. Domains of simian virus 40 large T-antigen exposed on the cell surface
CA2609633A1 (fr) Compositions de nicotinamide riboside
US6218162B1 (en) SH2-containing inositol-phosphatase
JP2001520508A (ja) インスリン抵抗性の治療
CA2204438A1 (fr) Peptides capables de se lier au domaine sh3 de la proteine gap, sequences nucleotidiques codant pour ces peptides, leur preparation et utilisation
Yanagi et al. Translocation, activation and association of protein‐tyrosine kinase (p72syk) with phosphatidylinositol 3‐kinase are early events during platelet activation
US6001354A (en) GRB2 associating polypeptides and nucleic acids encoding therefor
JPH09505730A (ja) Ｂｃｒ−ａｂｌ関連白血病および他の細胞増殖性疾患の治療方法ならびに組成物
Fashena et al. Transmembrane glycoprotein gp150 is a substrate for receptor tyrosine phosphatase DPTP10D in Drosophila cells
JP2006515159A (ja) Ｍｋ２相互作用タンパク質
JPH09511236A (ja) Ｃａｉ耐性タンパク質をコードするｄｎａおよびその使用
CA2184631A1 (fr) Produit et procede de regulation des voies de transduction de signaux
KR100482249B1 (ko) 단백질 타이로신 포스파타아제의 세포내 도메인에 대한 항체
AU699662C (en) Product and process for regulating signal transduction pathways
CA2598607A1 (fr) Methodes et compositions utilisees pour reguler le cycle cellulaire